🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Pharma Mar S.A.” Clear

  1. REGN4461 - Mibavademab

    Pharma Mar S.A.

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  2. REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508

    Pharma Mar S.A.

    Thromboembolic disease

    phase 3 small molecule active

    1 trial

  3. RITUXIMAB, Capsule, hard, Calquence 100 mg hard capsules, BENDAMUSTINE

    Pharma Mar S.A.

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  4. Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.

    Pharma Mar S.A.

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  5. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Pharma Mar S.A.

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  6. Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Pharma Mar S.A.

    Paroxysmal nocturnal haemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  7. Solution for Injection, subcutaneous Use, IMCIVREE 10 mg/ml solution for injection

    Pharma Mar S.A.

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial

  8. Sovateltide, Sovateltide matching placebo

    Pharma Mar S.A.

    Acute cerebral ischemic stroke

    phase 3 small molecule active

    1 trial

  9. Sterile normal saline (0.9% sodium chloride solution), ADX-324

    Pharma Mar S.A.

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  10. Sunitinib AqVida 12,5 mg Hartkapseln, QINLOCK 50 mg tablets

    Pharma Mar S.A.

    Patients with Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  11. T89 Placebo; capsules contain brown coated dripping pills., Nitroglycerin Orifarm 0,5 mg tabletes lietošanai zem mēles

    Pharma Mar S.A.

    Stable Angina Pectoris

    phase 3 small molecule active

    1 trial

  12. TASIMELTEON, HETLIOZ 20 mg hard capsules

    Pharma Mar S.A.

    Non-24 Hour Sleep-Wake Disorder

    phase 3 small molecule active

    1 trial

  13. TAXOL 6 mg/ml, concentrato per soluzione per infusione

    Pharma Mar S.A.

    Recurrent or Metastatic HER2 Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  14. TOPOTECAN, TOPOTECAN, IRINOTECAN, TOPOTECAN, lurbinectedin, TOPOTECAN

    Pharma Mar S.A.

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  15. Taldefgrobep, Placebo Solution for injection in pre-filled syringe, Taldefgrobep

    Pharma Mar S.A.

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  16. Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules

    Pharma Mar S.A.

    Newly diagnosed primary glioblastoma multiforme (ndGBM)

    phase 3 small molecule active

    1 trial

  17. Temomedac 20 mg hard capsules, Temomedac 5 mg hard capsules, Tirabrutinib, Temomedac 100 mg hard capsules, Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    Pharma Mar S.A.

    Relapsed/refractory primary central nervous system lymphoma

    phase 3 small molecule active

    1 trial

  18. The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.

    Pharma Mar S.A.

    treatment-resistant schizophrenia (TRS)

    phase 3 small molecule active

    1 trial

  19. The placebo has the same composition as the investigational medicinal product Clinitrat® (6.563+175,4+89,3+23,3) mg/sachet (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., CLINITRAT® (6.563+175,4+89,3+23,3) mg/sachet ή stick, Κόνις για πόσιμο διάλυμα

    Pharma Mar S.A.

    Second line treatment for colonoscopy preparation

    phase 3 small molecule active

    1 trial

  20. The placebo product is manufactured to visually match the corresponding FDY-5301 injection drug product. It is formulated to match a standard saline solution comprised of Sodium Chloride and Water for Injection.

    Pharma Mar S.A.

    Anterior ST-Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  21. Tildrakizumab Placebo Solution for Injection, TILDRAKIZUMAB

    Pharma Mar S.A.

    Moderate to Severe Genital Psoriasis

    phase 3 small molecule active

    1 trial

  22. Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab

    Pharma Mar S.A.

    Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis

    phase 3 small molecule active

    1 trial

  23. Tovorafenib, VINCRISIN 1 mg/ml solution injectable, 2 mg, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tovorafenib, VELBE 10 mg Trockensubstanz zur Injektionsbereitung, Vinblastin STADA 10 mg Pulver zur Herstellung einer Injektionslösung, cellcristin® 1 mg/ml Injektionslösung Wirkstoff: Vincristinsulfat, Vincristinesulfaat Teva 1 mg/ml, oplossing voor injectie, Vinblastinesulfaat 1 mg/ml PCH, oplossing voor injectie

    Pharma Mar S.A.

    Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

    phase 3 small molecule active

    1 trial

  24. Tradipitant

    Pharma Mar S.A.

    Idiopathic or diabetic gastroparesis with moderate to severe nausea.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources